Wellcome CRF, Imperial College, Hammersmith Campus
London, W12 0NN, United Kingdom
NCT Number: NCT02055898
The investigators wish to investigate whether enhancement of SWS, which is seen after a drug called sodium oxybate, reduces the impact of sleep disruption in CFS on daytime function, specifically sleepiness and mental performance. This is a safe and well-tolerated drug that is licensed for excessive daytime sleepiness (EDS) and cataplexy associated with narcolepsy.
The investigators will study 12 patients diagnosed with CFS using international diagnostic guidelines. The investigators will record overnight sleep with EEG (brainwave) measurement on the 1st and 4th nights of a 4 night period during which sodium oxybate and placebo will be taken nightly, and the investigators will measure next-day sleepiness, mental performance and fatigue, and compare drug and placebo nights.
Looking for future studies?
Notify Me25 year–65 year
All sexes
Interventional
Phase 4
London, W12 0NN, United Kingdom
Chronic fatigue syndrome (CFS), characterised by chronic disabling fatigue, sleep impairment and other symptoms, is associated with neither a currently identifiable disease process nor major psychiatric illness, and has an estimated prevalence in primary care of 1-2%. Sleep impairment is common in nearly everyone with CFS, with both daytime sleepiness and unrefreshing nighttime sleep reported, and consequent impact on daytime function. It may be that fundamental regulatory processes that control sleep are disturbed in CFS, leading to different effects on sleep and daytime symptoms depending on the subject's prior sleep, daytime routine, medication and other factors. The investigators contacts with patient groups have indicated that patients are generally confident that on days when their sleep is better they perform better in the day. There is growing evidence that deep, slow wave sleep (SWS) is altered in CFS, and this may suggest impairment of build up of sleep pressure during the day.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Xyrem
Time frame: night 1
Total power in 0.5-4Hz band in microvolts squared per Hertz (uV^2/Hz)
Time frame: night 4
Total power in 0.5-4Hz band in microvolts squared per Hertz (uV^2/Hz)
Time frame: Day 2
time to fall asleep in minutes
Time frame: Day 5
time to fall asleep in minutes
Imperial College London
Other
Slow-wave Sleep and Daytime Functioning in Chronic Fatigue Syndrome: Effects of Sodium Oxybate
Acronym: SAFFE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06128967
COVID-19, Chronic Disease
Belo Horizonte, Minas Gerais, Brazil
View Trial DetailsNCT03844412
Back Pain, Brain Diseases
Los Angeles, California, United States
View Trial DetailsNCT04740736
Chronic Disease, Chronic Fatigue Syndrome
New York, United States
View Trial DetailsNCT06245642
Chronic Disease, Chronic Fatigue Syndrome
Shanghai, Shanghai Municipality, China
View Trial Details